Edition:
India

People: Athersys Inc (ATHX.OQ)

ATHX.OQ on NASDAQ Stock Exchange Capital Market

1.63USD
1:30am IST
Change (% chg)

$-0.16 (-8.94%)
Prev Close
$1.79
Open
$1.80
Day's High
$1.80
Day's Low
$1.62
Volume
495,439
Avg. Vol
882,147
52-wk High
$4.38
52-wk Low
$1.14

Kola, Ismail 

Dr. Ismail Kola serves as Independent Director of the Company. Dr. Kola has served as a Director since October 2010. In retirement, Dr. Kola is a Senior Partner at Forepont Capital, a pharmaceutical venture capital company since April 2019. He was Executive Vice President of UCB S.A. in Belgium, a biopharmaceutical company dedicated to the development of innovative medicines focused on the fields of central nervous system and immunology disorders, and President of UCB New Medicines, UCB’s discovery research through to proof-of-concept in man organization, from November 2009 until his retirement in December 2017. Dr. Kola was formerly Senior Vice President, Discovery Research and Early Clinical Research & Experimental Medicine at Schering-Plough Research Institute, the pharmaceutical research arm of Schering-Plough Corporation, a pharmaceutical company, and Chief Scientific Officer at Schering-Plough Corporation, from March 2007 until his appointment at UCB. Prior to Schering-Plough, Dr. Kola held senior positions from January 2003 to March 2007 at Merck, a pharmaceutical company, where he was Senior Vice President and Site Head, Basic Research. From 2000 to 2003, Dr. Kola was Vice President, Research, and Global Head, Genomics Science and Biotechnology, at Pharmacia Corporation, a pharmaceutical company. Prior to his position with Pharmacia, Dr. Kola spent 15 years as Professor of Human Molecular Genetics and was Director of the Centre for Functional Genomics and Human Disease at Monash Medical School in Australia. Dr. Kola received his Ph.D. in Medicine from the University of Cape Town, South Africa, his B.Sc. from the University of South Africa, and his B.Pharm. from Rhodes University, South Africa. Dr. Kola served on the board of directors of Biotie Therapies, Inc. (NASDAQ: BITI) (and previously Synosia, who merged with Biotie) from February 2011 until May 2016 when it was sold to Acorda Therapeutics, where he also served on the compensation committee.

Basic Compensation

Total Annual Compensation, USD 48,500
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 48,800
Fiscal Year Total, USD 97,300

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --